ReviewCancers2022

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.

Tomas Koltai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.